Abstract The World Health Organization estimates that 71 million people worldwide have
chronic hepatitis C viral infection. A major challenge is overall lack of public awareness of …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

Today, hepatitis C virus infection affects up to 1.5 million people per year and is responsible
for 29 thousand deaths per year. In the 1970s, the clinical observation of unclear, transfusion …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

Introduction: The development of direct-acting antiviral (DAA) agents for the treatment of
hepatitis C virus (HCV) infection has completely transformed the management of this …

Aim The predictors for the development of hepatocellular carcinoma (HCC) after direct‐
acting antiviral (DAA) treatment were investigated. Methods A total of 1174 patients with …

Background Direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) result in initial
cure rates of 95% to 99% and re-treatment cure rates of 95%. Nevertheless, given the sheer …

Abstract Background and Aim Although treatment with direct‐acting antivirals has
dramatically improved morbidity and mortality attributable to chronic hepatitis C virus …

Background Although most currently used regimens for Hepatitis C virus (HCV) infections
can be initiated without prior knowledge of genotype and subtype, genotyping is still useful …

The time point of the most precise predictor of hepatocellular carcinoma (HCC) development
after viral eradication with direct-acting antiviral (DAA) therapy is unclear. In this study we …